Stifel lowered the firm’s price target on Bally’s (BALY) to $10 from $12 and keeps a Hold rating on the shares. Estimates are likely moving lower ...

Stifel raised the firm’s price target on Life360 (LIF) to $92 from $87 and keeps a Buy rating on the shares after Q2 results came in ahead of ...

Valneva confirmed its outlook for 2025, including expectations for total revenue between 180 million and 190 million euros. Total revenue last year was approximately 170 million euros. With Pfizer, ...

With the American consumer running out of breath amid an economic slowdown in the second half of 2025, Stifel sees a selloff of 10% or more in the S&P 500.

That is why Bannister, Carroll and their team of equity strategists have warned clients that investors are "whistling past the graveyard" in their latest report, which was recently shared with ...

Members of the team at Stifel posed with the Siouxland Chamber of Commerce and many others, on July 31, 2025, for a ribbon ...

Alcon Inc. (NYSE:ALC) ranks among the best medical stocks to buy according to analysts. On July 10, Stifel reaffirmed its Buy ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $126.25, a high estimate of ...

Stifel’s reaffirmation arrives even after a rough stretch for NOV: recent quarterly earnings have disappointed, with flat to ...

ST. LOUIS, June 11, 2025 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today announced that Victor Nesi, Co-President and Head of the Institutional Group, will retire from his day-to-day ...

Stifel’s initiation of coverage on NewAmsterdam with a Buy rating and a $44 price target reflects their confidence in the company’s potential to outperform within the pharmaceutical industry ...

Stifel Financial completes acquisition of Bryan Garnier, enhancing European capabilities in technology and healthcare investment banking.